{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:49:41Z","timestamp":1788871781062,"version":"build-2803163510"},"reference-count":35,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["30901375"],"award-info":[{"award-number":["30901375"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Beijing Natural Science Foundation","doi-asserted-by":"crossref","award":["7102125"],"award-info":[{"award-number":["7102125"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.imlet.2014.07.012","type":"journal-article","created":{"date-parts":[[2014,8,4]],"date-time":"2014-08-04T02:00:54Z","timestamp":1407117654000},"page":"206-213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Potentiation of anthrax vaccines using protective antigen-expressing viral replicon vectors"],"prefix":"10.1016","volume":"163","author":[{"given":"Hai-Chao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huai-Jie","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Zhou","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.imlet.2014.07.012_bib0005","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev.cellbio.19.111301.140655","article-title":"Anthrax toxin","volume":"19","author":"Collier","year":"2003","journal-title":"Annu Rev Cell Dev Biol"},{"key":"10.1016\/j.imlet.2014.07.012_bib0010","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1007\/s00018-004-4251-4","article-title":"Anthrax lethal toxin: a weapon of multisystem destruction","volume":"61","author":"Agrawal","year":"2004","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.imlet.2014.07.012_bib0015","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.addr.2005.01.028","article-title":"Molecular basis for improved anthrax vaccines","volume":"57","author":"Brey","year":"2005","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.imlet.2014.07.012_bib0020","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.mam.2009.08.006","article-title":"Anthrax vaccination strategies","volume":"30","author":"Cybulski","year":"2009","journal-title":"Mol Asp Med"},{"issue":"1","key":"10.1016\/j.imlet.2014.07.012_bib0025","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1600-065X.2010.00969.x","article-title":"Progress and novel strategies in vaccine development and treatment of anthrax","volume":"239","author":"Chitlaru","year":"2011","journal-title":"Immunol Rev"},{"key":"10.1016\/j.imlet.2014.07.012_bib0030","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1128\/IAI.74.2.1009-1015.2006","article-title":"Cytokine response and survival of mice immunized with an adenovirus expressing Bacillus anthracis protective antigen domain 4","volume":"74","author":"McConnell","year":"2006","journal-title":"Infect immun"},{"key":"10.1016\/j.imlet.2014.07.012_bib0035","doi-asserted-by":"crossref","first-page":"7529","DOI":"10.1016\/j.vaccine.2010.08.107","article-title":"Distinct immune responses of recombinant plasmid DNA replicon vaccines expressing two types of antigens with or without signal sequences","volume":"28","author":"Yu","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.imlet.2014.07.012_bib0040","doi-asserted-by":"crossref","first-page":"6313","DOI":"10.1016\/j.vaccine.2011.05.047","article-title":"Marked enhancement of the immune response to BioThrax (R) (anthrax vaccine adsorbed) by the TLR9 agonist CPG 7909 in healthy volunteers","volume":"29","author":"Rynkiewicz","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.imlet.2014.07.012_bib0045","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.molmed.2006.03.007","article-title":"Gene-based vaccines: recent technical and clinical advances","volume":"12","author":"Ulmer","year":"2006","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.imlet.2014.07.012_bib0050","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s11259-008-9040-3","article-title":"DNA vaccines and their applications in veterinary practice: current perspectives","volume":"32","author":"Dhama","year":"2008","journal-title":"Vet Res Commun"},{"key":"10.1016\/j.imlet.2014.07.012_bib0055","doi-asserted-by":"crossref","first-page":"536","DOI":"10.4161\/hv.5.8.8725","article-title":"Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults","volume":"5","author":"Keitel","year":"2009","journal-title":"Hum Vaccin"},{"key":"10.1016\/j.imlet.2014.07.012_bib0060","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ijpharm.2006.11.063","article-title":"PLGA-dendron nanoparticles enhance immunogenicity but not lethal antibody production of a DNA vaccine against anthrax in mice","volume":"331","author":"Ribeiro","year":"2007","journal-title":"Int J Pharm"},{"key":"10.1016\/j.imlet.2014.07.012_bib0065","doi-asserted-by":"crossref","first-page":"4872","DOI":"10.1016\/j.vaccine.2012.04.078","article-title":"Electroporation of a multivalent DNA vaccine cocktail elicits a protective immune response against anthrax and plague","volume":"30","author":"Albrecht","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.imlet.2014.07.012_bib0070","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/eji.201242690","article-title":"Three types of human CpG motifs differentially modulate and augment immunogenicity of non-viral and viral replicon DNA vaccines as built-in adjuvants","volume":"43","author":"Yu","year":"2013","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.imlet.2014.07.012_bib0075","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000053992","article-title":"Alphavirus vectors: applications for DNA vaccines production and gene expression","volume":"43","author":"Lundstrom","year":"2000","journal-title":"Intervirology"},{"key":"10.1016\/j.imlet.2014.07.012_bib0080","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nm813","article-title":"Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways","volume":"9","author":"Leitner","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.imlet.2014.07.012_bib0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1466252312000011","article-title":"Alphavirus replicon vaccines","volume":"13","author":"Vander Veen","year":"2012","journal-title":"Anim Health Res Rev"},{"key":"10.1016\/j.imlet.2014.07.012_bib0090","first-page":"51","article-title":"Enhancement of tumor-specific immune response with plasmid DNA replicon vectors","volume":"60","author":"Leitner","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.imlet.2014.07.012_bib0095","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1099\/vir.0.80481-0","article-title":"Enhanced immunogenicity using an alphavirus replicon DNA vaccine against human immunodeficiency virus type 1","volume":"86","author":"Nordstrom","year":"2005","journal-title":"J Gen Virol"},{"key":"10.1016\/j.imlet.2014.07.012_bib0100","doi-asserted-by":"crossref","first-page":"8843","DOI":"10.1016\/j.vaccine.2007.10.016","article-title":"Enhanced immune responses using plasmid DNA replicon vaccine encoding the Hc domain of Clostridium botulinum neurotoxin serotype A","volume":"25","author":"Yu","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.imlet.2014.07.012_bib0105","doi-asserted-by":"crossref","first-page":"13412","DOI":"10.1128\/JVI.01799-07","article-title":"Increased immunogenicity of a DNA-launched Venezuelan equine encephalitis virus-based replicon DNA vaccine","volume":"81","author":"Ljungberg","year":"2007","journal-title":"J Virol"},{"key":"10.1016\/j.imlet.2014.07.012_bib0110","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1128\/JVI.06535-11","article-title":"Superior induction of T cell responses to conserved HIV-1 regions by electroporated alphavirus replicon DNA compared to that with conventional plasmid DNA vaccine","volume":"86","author":"Knudsen","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.imlet.2014.07.012_bib0115","doi-asserted-by":"crossref","first-page":"242","DOI":"10.4161\/hv.22888","article-title":"In vitro and in vivo activities of recombinant anthrax protective antigen co-expressed with thioredoxin in Escherichia coli","volume":"9","author":"Ma","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.imlet.2014.07.012_bib0120","doi-asserted-by":"crossref","first-page":"6148","DOI":"10.1016\/j.vaccine.2009.08.022","article-title":"Individual and bivalent vaccines against botulinum neurotoxin serotypes A and B using DNA-based Semliki Forest virus vectors","volume":"27","author":"Yu","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.imlet.2014.07.012_bib0125","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jbiotec.2012.08.012","article-title":"The future of human DNA vaccines","volume":"162","author":"Li","year":"2012","journal-title":"J Biotechnol"},{"key":"10.1016\/j.imlet.2014.07.012_bib0130","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s12026-008-8076-3","article-title":"DNA vaccines: developing new strategies to enhance immune responses","volume":"42","author":"Abdulhaqq","year":"2008","journal-title":"Immunol Res"},{"key":"10.1016\/j.imlet.2014.07.012_bib0135","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1586\/erv.11.188","article-title":"Technologies for enhanced efficacy of DNA vaccines","volume":"11","author":"Saade","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.imlet.2014.07.012_bib0140","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.vaccine.2013.03.046","article-title":"Potent tetravalent replicon vaccines against botulinum neurotoxins using DNA-based Semliki Forest virus replicon vectors","volume":"31","author":"Yu","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.imlet.2014.07.012_bib0145","doi-asserted-by":"crossref","first-page":"5110","DOI":"10.1016\/j.vaccine.2006.04.059","article-title":"Type I Interferons are essential for the efficacy of replicase-based DNA vaccines","volume":"24","author":"Leitner","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.imlet.2014.07.012_bib0150","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1743-422X-8-36","article-title":"Role of innate signaling pathways in the immunogenicity of alphaviral replicon-based vaccines","volume":"8","author":"N\u00e4slund","year":"2011","journal-title":"Virol J"},{"key":"10.1016\/j.imlet.2014.07.012_bib0155","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1016\/j.vaccine.2007.11.072","article-title":"Plasmid-based vaccination with candidate anthrax vaccine antigens induces durable type 1 and type 2 T-helper immune responses","volume":"26","author":"Zhang","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.imlet.2014.07.012_bib0160","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/eji.200838058","article-title":"Anthrax protective antigen administered by DNA vaccination to distinct subcellular locations potentiates humoral and cellular immune responses","volume":"39","author":"Midha","year":"2009","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.imlet.2014.07.012_bib0165","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1128\/IAI.71.3.1491-1496.2003","article-title":"Venezuelan equine encephalitis virus vectored vaccines protect mice against anthrax spore challenge","volume":"71","author":"Lee","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.imlet.2014.07.012_bib0170","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1371\/journal.ppat.0030142","article-title":"A viral nanoparticle with dual function as an anthrax antitoxin and vaccine","volume":"3","author":"Manayani","year":"2007","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.imlet.2014.07.012_bib0175","doi-asserted-by":"crossref","first-page":"5814","DOI":"10.1016\/j.vaccine.2008.08.031","article-title":"Chimeric hepatitis B virus core particles carrying an epitope of anthrax protective antigen induce protective immunity against Bacillus anthracis","volume":"26","author":"Yin","year":"2008","journal-title":"Vaccine"}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247814001527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247814001527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T01:31:20Z","timestamp":1538357480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247814001527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0165247814001527"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2014.07.012","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potentiation of anthrax vaccines using protective antigen-expressing viral replicon vectors","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2014.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}